Antiobesity Medication Use Among Overweight and Obese Adults in the United States: 2015-2018.

Autor:	MacEwan J; PRECISIONheor, Los Angeles, California; Genesis Research, Hoboken, New Jersey. Electronic address: jmacewan@genesisrg.com., Kan H; Eli Lilly and Company, Indianapolis, Indiana., Chiu K; PRECISIONheor, Los Angeles, California., Poon JL; Eli Lilly and Company, Indianapolis, Indiana., Shinde S; Eli Lilly and Company, Indianapolis, Indiana., Ahmad NN; Eli Lilly and Company, Indianapolis, Indiana.
Jazyk:	angličtina
Zdroj:	Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists [Endocr Pract] 2021 Nov; Vol. 27 (11), pp. 1139-1148. Date of Electronic Publication: 2021 Jul 12.
DOI:	10.1016/j.eprac.2021.07.004
Abstrakt:	Objective: To estimate the utilization of U.S. Food and Drug Administration- approved prescription antiobesity medications (AOMs) and to identify factors associated with AOM use in the United States. Methods: Respondents aged ≥18 years meeting AOM eligibility criteria in the 2015-2016 and 2017-2018 National Health and Nutrition Examination Survey and the 2016 Medical Expenditure Panel Survey were included in the study. AOM eligibility was defined as having a body mass index (BMI) of ≥30 kg/m 2 or having a BMI between 27 and 29.9 kg/m 2 and at least 1 obesity-related comorbidity. Demographic, socioeconomic, and clinical characteristics, economic outcomes, and health-related quality of life were summarized and compared between AOM users and nonusers. Multivariable logistic regression was used to identify factors that were associated with AOM use. Results: Only 0.80% of eligible adults reported using AOMs in the past 30 days in 2015-2016 and 2017-2018 National Health and Nutrition Examination Survey. A greater proportion of current AOM users previously tried dietary changes compared with nonusers. They also reported an average weight loss of 3.1 kg over the previous year compared with a 1.5-kg gain among the nonusers. The total health care costs trended higher among AOM users, driven mostly by higher outpatient service costs. A BMI of ≥30 kg/m 2 , depression, dyslipidemia, and infertility predicted AOM use, whereas Medicare and being at risk of sleep apnea were associated with lower odds of AOM use. Conclusion: Despite the availability of newer AOMs and their inclusion in medical treatment guidelines, the utilization of AOMs remains low. This may reflect under-prescribing of and/or restricted patient access to approved evidence-based pharmacotherapy for obesity. (Copyright © 2021 AACE. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu